GlassScriptPhysician profile
Adam J Maass
NPI 1841258738
$502,366.83
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213K · 2020: $152K · 2021: $127K · 2022: $11K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $303,770.34 | 2019-2021 | |
| Novo Nordisk INC | $114,946.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,705.45 | 2019-2022 | |
| Chiasma, INC. | $14,005.10 | 2021 | |
| Abbvie INC. | $12,972.05 | 2019-2022 | |
| Dexcom, INC. | $12,302.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $5,957.52 | 2019 | |
| Xeris Pharmaceuticals, INC. | $5,413.87 | 2020-2022 | |
| Insulet Corporation | $3,474.82 | 2021-2022 | |
| Abbott Laboratories | $848.63 | 2019-2022 | |
| Eli Lilly and Company | $746.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $554.65 | 2019-2021 | |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Genzyme Corporation | $200.00 | 2019 | |
| Tandem Diabetes Care, INC. | $162.80 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $150.38 | 2019-2022 | |
| Antares Pharma, INC. | $125.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $102.86 | 2019 | |
| Pfizer INC. | $87.91 | 2019 | |
| Horizon Therapeutics Plc | $86.38 | 2021 | |
| Valeritas, INC. | $84.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.54 | 2020-2021 | |
| Zealand Pharma US, INC. | $62.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.62 | 2022 | |
| Medtronic Minimed, INC. | $20.53 | 2019 | |
| Becton, Dickinson and Company | $17.91 | 2021 | |
| Recordati_rare_diseases_inc. | $16.88 | 2021 | |
| Medtronic, INC. | $14.04 | 2021 | |
| Corcept Therapeutics | $13.47 | 2019 | |
| Ibsa Pharma INC. | $12.54 | 2021 | |
| Roche Diabetes Care, INC. | $11.20 | 2019 | |
| Shire North American Group INC | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Maass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.